Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission

Julie M. Vose; Douglas J. Rizzo; Jing Tao-Wu; James O. Armitage; Asad Bashey; Linda J. Burns; Neal Paul Christiansen; Cesar O. Freytes; Robert Peter Gale; John Gibson; Sergio A. Giralt; Roger H. Herzig; Charles F. Lemaistre; Philip L. McCarthy; Stephen D. Nimer; Finn B. Petersen; David P. Schenkein; Peter H. Wiernik; Joseph M. Wiley; Fausto R. Loberiza; Hillard M. Lazarus; Koen van Biesen; Mary M. Horowitz

doi:10.1016/j.bbmt.2003.09.015

Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission

Julie M. Vose, Douglas J. Rizzo, Jing Tao-Wu, James O. Armitage, Asad Bashey, Linda J. Burns, Neal Paul Christiansen, Cesar O. Freytes, Robert Peter Gale, John Gibson, Sergio A. Giralt, Roger H. Herzig, Charles F. Lemaistre, Philip L. McCarthy, Stephen D. Nimer, Finn B. Petersen, David P. Schenkein, Peter H. Wiernik, Joseph M. Wiley, Fausto R. LoberizaHillard M. Lazarus, Koen van Biesen, Mary M. Horowitz

Mays Cancer Center

Research output: Contribution to journal › Article

43 Scopus citations

Abstract

We evaluated the results of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with diffuse aggressive non-Hodgkin lymphoma (NHL) in first relapse (Rel 1) or second complete remission (CR 2). Data were evaluated from the Autologous Blood and Marrow Transplant Registry on 429 patients with diffuse aggressive NHL who underwent transplantation in Rel 1 or CR 2. Transplantations were performed between 1989 and 1996 and were reported to the Autologous Blood and Marrow Transplant Registry by 93 centers in North and South America. The probability of 3-year survival was 44% (95% confidence interval [CI], 33%-55%). The probability at 3 years of progression-free survival was 31% (95% CI, 27%-36%). Patients who underwent transplantation in CR 2 had a 3-year probability of progression-free survival of 38% (95% CI, 30%-46%) compared with 28% (95% CI, 22%-33%) for those who were not in remission at the time of transplantation (P<.001). In multivariate analysis, chemotherapy resistance, increased lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age ≥40 years, and use of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of survival. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with diffuse aggressive NHL in CR 2 or Rel 1 resulted in better outcome for patients with chemotherapy-sensitive disease, longer relapse-free intervals, and age <40 years. Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death.

Original language	English (US)
Pages (from-to)	116-127
Number of pages	12
Journal	Biology of Blood and Marrow Transplantation
Volume	10
Issue number	2
DOIs	https://doi.org/10.1016/j.bbmt.2003.09.015
State	Published - Feb 1 2004

Keywords

Hematopoietic stem cell transplantation
High-dose chemotherapy
Non-Hodgkin lymphoma

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2003.09.015

Fingerprint Dive into the research topics of 'Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission'. Together they form a unique fingerprint.

Cite this

Vose, J. M., Rizzo, D. J., Tao-Wu, J., Armitage, J. O., Bashey, A., Burns, L. J., Christiansen, N. P., Freytes, C. O., Gale, R. P., Gibson, J., Giralt, S. A., Herzig, R. H., Lemaistre, C. F., McCarthy, P. L., Nimer, S. D., Petersen, F. B., Schenkein, D. P., Wiernik, P. H., Wiley, J. M., ... Horowitz, M. M. (2004). Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission. Biology of Blood and Marrow Transplantation, 10(2), 116-127. https://doi.org/10.1016/j.bbmt.2003.09.015

Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission. / Vose, Julie M.; Rizzo, Douglas J.; Tao-Wu, Jing; Armitage, James O.; Bashey, Asad; Burns, Linda J.; Christiansen, Neal Paul; Freytes, Cesar O.; Gale, Robert Peter; Gibson, John; Giralt, Sergio A.; Herzig, Roger H.; Lemaistre, Charles F.; McCarthy, Philip L.; Nimer, Stephen D.; Petersen, Finn B.; Schenkein, David P.; Wiernik, Peter H.; Wiley, Joseph M.; Loberiza, Fausto R.; Lazarus, Hillard M.; van Biesen, Koen; Horowitz, Mary M.

In: Biology of Blood and Marrow Transplantation, Vol. 10, No. 2, 01.02.2004, p. 116-127.

Research output: Contribution to journal › Article

Vose, JM, Rizzo, DJ, Tao-Wu, J, Armitage, JO, Bashey, A, Burns, LJ, Christiansen, NP, Freytes, CO, Gale, RP, Gibson, J, Giralt, SA, Herzig, RH, Lemaistre, CF, McCarthy, PL, Nimer, SD, Petersen, FB, Schenkein, DP, Wiernik, PH, Wiley, JM, Loberiza, FR, Lazarus, HM, van Biesen, K & Horowitz, MM 2004, 'Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission', Biology of Blood and Marrow Transplantation, vol. 10, no. 2, pp. 116-127. https://doi.org/10.1016/j.bbmt.2003.09.015

Vose, Julie M. ; Rizzo, Douglas J. ; Tao-Wu, Jing ; Armitage, James O. ; Bashey, Asad ; Burns, Linda J. ; Christiansen, Neal Paul ; Freytes, Cesar O. ; Gale, Robert Peter ; Gibson, John ; Giralt, Sergio A. ; Herzig, Roger H. ; Lemaistre, Charles F. ; McCarthy, Philip L. ; Nimer, Stephen D. ; Petersen, Finn B. ; Schenkein, David P. ; Wiernik, Peter H. ; Wiley, Joseph M. ; Loberiza, Fausto R. ; Lazarus, Hillard M. ; van Biesen, Koen ; Horowitz, Mary M. / Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission. In: Biology of Blood and Marrow Transplantation. 2004 ; Vol. 10, No. 2. pp. 116-127.

@article{d4448e968d0443e987b40b40538acc25,

title = "Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission",

abstract = "We evaluated the results of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with diffuse aggressive non-Hodgkin lymphoma (NHL) in first relapse (Rel 1) or second complete remission (CR 2). Data were evaluated from the Autologous Blood and Marrow Transplant Registry on 429 patients with diffuse aggressive NHL who underwent transplantation in Rel 1 or CR 2. Transplantations were performed between 1989 and 1996 and were reported to the Autologous Blood and Marrow Transplant Registry by 93 centers in North and South America. The probability of 3-year survival was 44% (95% confidence interval [CI], 33%-55%). The probability at 3 years of progression-free survival was 31% (95% CI, 27%-36%). Patients who underwent transplantation in CR 2 had a 3-year probability of progression-free survival of 38% (95% CI, 30%-46%) compared with 28% (95% CI, 22%-33%) for those who were not in remission at the time of transplantation (P<.001). In multivariate analysis, chemotherapy resistance, increased lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age ≥40 years, and use of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of survival. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with diffuse aggressive NHL in CR 2 or Rel 1 resulted in better outcome for patients with chemotherapy-sensitive disease, longer relapse-free intervals, and age <40 years. Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death.",

keywords = "Hematopoietic stem cell transplantation, High-dose chemotherapy, Non-Hodgkin lymphoma",

author = "Vose, {Julie M.} and Rizzo, {Douglas J.} and Jing Tao-Wu and Armitage, {James O.} and Asad Bashey and Burns, {Linda J.} and Christiansen, {Neal Paul} and Freytes, {Cesar O.} and Gale, {Robert Peter} and John Gibson and Giralt, {Sergio A.} and Herzig, {Roger H.} and Lemaistre, {Charles F.} and McCarthy, {Philip L.} and Nimer, {Stephen D.} and Petersen, {Finn B.} and Schenkein, {David P.} and Wiernik, {Peter H.} and Wiley, {Joseph M.} and Loberiza, {Fausto R.} and Lazarus, {Hillard M.} and {van Biesen}, Koen and Horowitz, {Mary M.}",

year = "2004",

month = feb,

day = "1",

doi = "10.1016/j.bbmt.2003.09.015",

language = "English (US)",

volume = "10",

pages = "116--127",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission

AU - Vose, Julie M.

AU - Rizzo, Douglas J.

AU - Tao-Wu, Jing

AU - Armitage, James O.

AU - Bashey, Asad

AU - Burns, Linda J.

AU - Christiansen, Neal Paul

AU - Freytes, Cesar O.

AU - Gale, Robert Peter

AU - Gibson, John

AU - Giralt, Sergio A.

AU - Herzig, Roger H.

AU - Lemaistre, Charles F.

AU - McCarthy, Philip L.

AU - Nimer, Stephen D.

AU - Petersen, Finn B.

AU - Schenkein, David P.

AU - Wiernik, Peter H.

AU - Wiley, Joseph M.

AU - Loberiza, Fausto R.

AU - Lazarus, Hillard M.

AU - van Biesen, Koen

AU - Horowitz, Mary M.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - We evaluated the results of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with diffuse aggressive non-Hodgkin lymphoma (NHL) in first relapse (Rel 1) or second complete remission (CR 2). Data were evaluated from the Autologous Blood and Marrow Transplant Registry on 429 patients with diffuse aggressive NHL who underwent transplantation in Rel 1 or CR 2. Transplantations were performed between 1989 and 1996 and were reported to the Autologous Blood and Marrow Transplant Registry by 93 centers in North and South America. The probability of 3-year survival was 44% (95% confidence interval [CI], 33%-55%). The probability at 3 years of progression-free survival was 31% (95% CI, 27%-36%). Patients who underwent transplantation in CR 2 had a 3-year probability of progression-free survival of 38% (95% CI, 30%-46%) compared with 28% (95% CI, 22%-33%) for those who were not in remission at the time of transplantation (P<.001). In multivariate analysis, chemotherapy resistance, increased lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age ≥40 years, and use of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of survival. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with diffuse aggressive NHL in CR 2 or Rel 1 resulted in better outcome for patients with chemotherapy-sensitive disease, longer relapse-free intervals, and age <40 years. Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death.

AB - We evaluated the results of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with diffuse aggressive non-Hodgkin lymphoma (NHL) in first relapse (Rel 1) or second complete remission (CR 2). Data were evaluated from the Autologous Blood and Marrow Transplant Registry on 429 patients with diffuse aggressive NHL who underwent transplantation in Rel 1 or CR 2. Transplantations were performed between 1989 and 1996 and were reported to the Autologous Blood and Marrow Transplant Registry by 93 centers in North and South America. The probability of 3-year survival was 44% (95% confidence interval [CI], 33%-55%). The probability at 3 years of progression-free survival was 31% (95% CI, 27%-36%). Patients who underwent transplantation in CR 2 had a 3-year probability of progression-free survival of 38% (95% CI, 30%-46%) compared with 28% (95% CI, 22%-33%) for those who were not in remission at the time of transplantation (P<.001). In multivariate analysis, chemotherapy resistance, increased lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age ≥40 years, and use of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of survival. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with diffuse aggressive NHL in CR 2 or Rel 1 resulted in better outcome for patients with chemotherapy-sensitive disease, longer relapse-free intervals, and age <40 years. Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death.

KW - Hematopoietic stem cell transplantation

KW - High-dose chemotherapy

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0742323747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742323747&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2003.09.015

DO - 10.1016/j.bbmt.2003.09.015

M3 - Article

C2 - 14750077

AN - SCOPUS:0742323747

VL - 10

SP - 116

EP - 127

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -